Cardiol Therapeutics Inc. (CRDL)
USD 1.14
(1.79%)
USD 1.14
(1.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 36.7 Million CAD | -40.83% |
| 2022 | 62.02 Million CAD | -29.41% |
| 2021 | 87.87 Million CAD | 452.92% |
| 2020 | 15.89 Million CAD | 2.52% |
| 2019 | 15.5 Million CAD | -37.2% |
| 2018 | 24.68 Million CAD | 666.45% |
| 2017 | 3.22 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 26.31 Million CAD | -15.46% |
| 2024 Q1 | 31.12 Million CAD | -15.19% |
| 2023 Q4 | 36.7 Million CAD | -14.76% |
| 2023 Q2 | 47.16 Million CAD | -10.47% |
| 2023 Q1 | 52.68 Million CAD | -15.06% |
| 2023 FY | 36.7 Million CAD | -40.83% |
| 2023 Q3 | 43.05 Million CAD | -8.73% |
| 2022 Q2 | 74.26 Million CAD | -6.51% |
| 2022 Q3 | 68.35 Million CAD | -7.95% |
| 2022 FY | 62.02 Million CAD | -29.41% |
| 2022 Q1 | 79.43 Million CAD | -9.61% |
| 2022 Q4 | 62.02 Million CAD | -9.26% |
| 2021 Q1 | 21.09 Million CAD | 32.75% |
| 2021 FY | 87.87 Million CAD | 452.92% |
| 2021 Q4 | 87.87 Million CAD | 176.94% |
| 2021 Q3 | 31.73 Million CAD | -13.65% |
| 2021 Q2 | 36.74 Million CAD | 74.19% |
| 2020 Q1 | 13.35 Million CAD | -13.88% |
| 2020 FY | 15.89 Million CAD | 2.52% |
| 2020 Q4 | 15.89 Million CAD | -35.01% |
| 2020 Q3 | 24.45 Million CAD | -10.82% |
| 2020 Q2 | 27.42 Million CAD | 105.38% |
| 2019 Q3 | 18.3 Million CAD | -10.87% |
| 2019 Q2 | 20.53 Million CAD | -10.38% |
| 2019 Q1 | 22.91 Million CAD | -7.17% |
| 2019 FY | 15.5 Million CAD | -37.2% |
| 2019 Q4 | 15.5 Million CAD | -15.3% |
| 2018 Q4 | 24.68 Million CAD | 88.52% |
| 2018 FY | 24.68 Million CAD | 666.45% |
| 2018 Q1 | 2.85 Million CAD | -11.39% |
| 2018 Q2 | 12.14 Million CAD | 325.52% |
| 2018 Q3 | 13.09 Million CAD | 7.82% |
| 2017 FY | 3.22 Million CAD | 0.0% |
| 2017 Q4 | 3.22 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 205.79 Million USD | 82.167% |
| Theratechnologies Inc. | 77.76 Million USD | 52.808% |
| Safety Shot Inc | 12.7 Million USD | -188.772% |
| Cosmos Health Inc. | 66.29 Million USD | 44.641% |
| Cronos Group Inc. | 1.13 Billion USD | 96.764% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 92.209% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 34.404% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 92.022% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 31.127% |
| ProPhase Labs, Inc. | 91.92 Million USD | 60.076% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -146.428% |
| Dynavax Technologies Corporation | 997.09 Million USD | 96.319% |
| Radius Health, Inc. | 1.71 Billion USD | 97.861% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -58.691% |
| Alvotech | 950.09 Million USD | 96.137% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -34.203% |
| Alpha Teknova, Inc. | 128.58 Million USD | 71.459% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 94.961% |
| SCYNEXIS, Inc. | 128.41 Million USD | 71.42% |
| Harrow Health, Inc. | 311.75 Million USD | 88.228% |
| Biofrontera Inc. | 27.93 Million USD | -31.392% |
| DURECT Corporation | 45.18 Million USD | 18.784% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 97.395% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 95.942% |
| OptiNose, Inc. | 107.72 Million USD | 65.933% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -59.241% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 36.082% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 55.121% |
| SIGA Technologies, Inc. | 254.83 Million USD | 85.598% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 86.591% |
| Shineco, Inc. | 84.17 Million USD | 56.402% |
| Phibro Animal Health Corporation | 982.18 Million USD | 96.263% |
| Procaps Group S.A. | 460.18 Million USD | 92.025% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 15.259% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -334.932% |
| Viatris Inc. | 47.68 Billion USD | 99.923% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -34.203% |
| Rockwell Medical, Inc. | 52.17 Million USD | 29.656% |
| Incannex Healthcare Limited | 17.04 Million USD | -115.29% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 68.923% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.153% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 96.79% |
| PetIQ, Inc. | 868.22 Million USD | 95.773% |
| Silver Spike Investment Corp. | 88.57 Million USD | 58.566% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.871% |
| Journey Medical Corporation | 76.84 Million USD | 52.243% |
| Alimera Sciences, Inc. | 153.52 Million USD | 76.095% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -8.595% |
| Assertio Holdings, Inc. | 286.41 Million USD | 87.186% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -516.635% |
| Embecta Corp. | 1.21 Billion USD | 96.978% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -177.036% |
| Procaps Group, S.A. | 460.18 Million USD | 92.025% |
| PainReform Ltd. | 9.93 Million USD | -269.592% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 85.945% |
| Hempacco Co., Inc. | 18.04 Million USD | -103.405% |
| Talphera, Inc. | 20.39 Million USD | -79.949% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 97.669% |
| Alvotech | 950.09 Million USD | 96.137% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 97.777% |
| Kamada Ltd. | 351.96 Million USD | 89.573% |
| Indivior PLC | 1.95 Billion USD | 98.119% |
| Currenc Group, Inc. | 141.49 Million USD | 74.061% |
| Evoke Pharma, Inc. | 7.06 Million USD | -419.209% |
| Flora Growth Corp. | 23.62 Million USD | -55.339% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -177.036% |
| Evolus, Inc. | 188.99 Million USD | 80.582% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 97.132% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 97.574% |
| Akanda Corp. | 8.83 Million USD | -315.164% |